10x Genomics Quarterly Income Statement
NASDAQ: TXGIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
10x Genomics revenue and earnings
In the quarter ended Jun 30, 2026, 10x Genomics generated $151.0 million in revenue, down 12.6% from the same quarter a year earlier. 10x Genomics reported a net loss of $17.9 million, compared with net income of $34.5 million a year earlier. Gross margin was 74.5% (up from 72.3%) and operating margin -12.9%.
Diluted earnings per share came in at -$0.14, down from $0.28.
Summary generated from market data by MetaCap's automated system. Methodology
10x Genomics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 151.04M | 150.84M | 166.03M | 149.00M | 172.91M | 154.88M | 165.02M | 151.65M | 153.10M | 141.01M | 183.98M | 153.64M |
| Revenue growth (YoY) | -12.65% | -2.61% | +0.61% | -1.75% | +12.93% | +9.84% | -10.30% | -1.30% | +4.28% | +5.01% | +17.76% | +17.22% |
| Cost of Revenue | 38.54M | 44.66M | 52.98M | 48.70M | 47.82M | 49.44M | 54.07M | 45.26M | 48.88M | 48.09M | 68.20M | 58.12M |
| Gross Profit | 112.50M | 106.18M | 113.05M | 100.31M | 125.08M | 105.44M | 110.95M | 106.39M | 104.22M | 92.91M | 115.78M | 95.53M |
| Operating Expenses | 132.05M | 123.22M | 132.59M | 132.55M | 94.96M | 144.77M | 160.79M | 147.88M | 145.96M | 154.41M | 170.97M | 190.32M |
| Research & Development | 56.79M | 56.85M | 55.97M | 57.19M | 61.22M | 64.25M | 66.97M | 66.17M | 62.92M | 68.64M | 65.27M | 66.51M |
| Selling, General & Admin | 78.66M | 66.38M | 76.62M | 75.36M | 74.43M | 89.73M | 93.83M | 81.70M | 83.04M | 85.77M | 86.13M | 82.42M |
| Operating Income | -19.55M | -17.05M | -19.54M | -32.24M | 30.13M | -39.33M | -49.84M | -41.48M | -41.74M | -61.50M | -55.19M | -94.80M |
| Interest Expense | 0 | — | 0 | -3.00K | 3.00K | 0 | 0 | 2.00K | 1.00K | 1.00K | 8.00K | 1.00K |
| Other Income (Expense) | 910.00K | 4.20M | 4.35M | 4.04M | 6.87M | 5.82M | 1.46M | 7.05M | 4.66M | 3.69M | 8.59M | 3.05M |
| Pretax Income | -18.64M | -12.85M | -15.19M | -28.20M | 37.00M | -33.51M | -48.38M | -34.44M | -37.08M | -57.80M | -46.60M | -91.74M |
| Income Tax | -714.00K | 623.00K | 1.06M | -733.00K | 2.46M | 852.00K | 648.00K | 1.31M | 818.00K | 2.15M | 2.35M | 1.24M |
| Net Income | -17.93M | -13.47M | -16.25M | -27.47M | 34.54M | -34.36M | -49.03M | -35.75M | -37.90M | -59.95M | -48.95M | -92.99M |
| Net Income growth (YoY) | -151.92% | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.14 | -0.10 | -0.13 | -0.22 | 0.28 | -0.28 | -0.40 | -0.30 | -0.32 | -0.50 | -0.42 | -0.79 |
| EPS (Diluted) | -0.14 | -0.10 | -0.13 | -0.22 | 0.28 | -0.28 | -0.40 | -0.30 | -0.32 | -0.50 | -0.42 | -0.79 |
| Shares Outstanding (Basic) | 129.98M | 128.29M | — | 125.50M | 123.76M | 122.61M | — | 120.73M | 120.07M | 119.39M | — | 117.73M |
| Shares Outstanding (Diluted) | 129.98M | 128.29M | — | 125.50M | 124.51M | 122.61M | — | 120.73M | 120.07M | 119.39M | — | 117.73M |
| EBITDA | -9.89M | -7.09M | -9.48M | -21.95M | 37.94M | -31.31M | -41.09M | -32.52M | -32.77M | -52.30M | -45.47M | -85.42M |
| Gross Margin | 74.48% | 70.39% | 68.09% | 67.32% | 72.34% | 68.08% | 67.24% | 70.16% | 68.07% | 65.89% | 62.93% | 62.18% |
| Operating Margin | -12.95% | -11.30% | -11.77% | -21.64% | 17.42% | -25.39% | -30.20% | -27.36% | -27.26% | -43.61% | -30.00% | -61.70% |
| Net Margin | -11.87% | -8.93% | -9.79% | -18.44% | 19.97% | -22.18% | -29.71% | -23.58% | -24.75% | -42.52% | -26.61% | -60.52% |
This table shows 12 quarterly periods of 10x Genomics's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TXG's reporting calendar. What is a income statement?